Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

VENCLEXTA®

News, A to Z Feature 30/04/2025

A to Z: Drugs in Highlight: V is for VENCLEXTA®

Tariffs

News 29/04/2025

The Role of IP Royalties in Mitigating the Financial Effects of Tariffs

Networking Breakfast

Events, News, Team news 27/04/2025

Protecting Your Innovation: An Intellectual Property (IP) Breakfast for Businesses and Innovators

A To Z Drugs In Highlight U Is For UPTRAVI

News, A to Z Feature 24/04/2025

A to Z: Drugs in Highlight: U is for UPTRAVI®

A To Z Drugs In Highlight T Is For TECFIDERA®

News, A to Z Feature 17/04/2025

A to Z: Drugs in Highlight: T is for TECFIDERA®

European, News 16/04/2025

Updated European Patent Office Examination Guidelines for AI Inventions

Use It Or Lose It A Reminder To The Holders Of Comparable Registrations Main

European, News 15/04/2025

Use it or Lose it: A reminder to the holders of Comparable Registrations

STRIBILD

News, A to Z Feature 10/04/2025

A to Z: Drugs in Highlight: S is for STRIBILD®

Seas The Day Start

Events, News 08/04/2025

Seas The Day: Pacific Row Begins - Follow Their Epic Journey

1 2 3 4 5 6